Benefits and costs of recombinant human erythropoietin for end-stage renal failure: A review benefits and costs of erythropoietin

Paul McNamee; Eddy van Doorslaer; Rob Segaar

doi:10.1017/S0266462300005419

Benefits and costs of recombinant human erythropoietin for end-stage renal failure: A review benefits and costs of erythropoietin

Paul McNamee, Eddy van Doorslaer, Rob Segaar

Research output: Contribution to journal › Article › Academic › peer-review

13 Citations (Scopus)

Abstract

Recombinant human erythropoietin is an efficacious therapy in treatment of the anemia of end-stage renal failure. However, the scale of impact on quality of life and medical care resources remains uncertain. By reviewing the literature we evaluate cost-effectiveness of recombinant human erythropoietin and show how previous studies may have implicitly overestimated cost-effectiveness.

Original language	English
Pages (from-to)	490-504
Number of pages	15
Journal	International Journal of Technology Assessment in Health Care
Volume	9
Issue number	4
DOIs	https://doi.org/10.1017/S0266462300005419
Publication status	Published - 1993

Bibliographical note

Funding Information:
The authors acknowledge the financial support of the Dutch Health Council. We also thank Anton van Boxtel of the Health Council for his help in providing us with data from a survey conducted by Dialyse Groep Nederland.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1017/S0266462300005419

Cite this

@article{f12261bb846b429aae65cac3e1d0e305,

title = "Benefits and costs of recombinant human erythropoietin for end-stage renal failure: A review benefits and costs of erythropoietin",

abstract = "Recombinant human erythropoietin is an efficacious therapy in treatment of the anemia of end-stage renal failure. However, the scale of impact on quality of life and medical care resources remains uncertain. By reviewing the literature we evaluate cost-effectiveness of recombinant human erythropoietin and show how previous studies may have implicitly overestimated cost-effectiveness.",

author = "Paul McNamee and {van Doorslaer}, Eddy and Rob Segaar",

note = "Funding Information: The authors acknowledge the financial support of the Dutch Health Council. We also thank Anton van Boxtel of the Health Council for his help in providing us with data from a survey conducted by Dialyse Groep Nederland.",

year = "1993",

doi = "10.1017/S0266462300005419",

language = "English",

volume = "9",

pages = "490--504",

journal = "International Journal of Technology Assessment in Health Care",

issn = "0266-4623",

publisher = "Cambridge University Press",

number = "4",

}

TY - JOUR

T1 - Benefits and costs of recombinant human erythropoietin for end-stage renal failure

T2 - A review benefits and costs of erythropoietin

AU - McNamee, Paul

AU - van Doorslaer, Eddy

AU - Segaar, Rob

N1 - Funding Information: The authors acknowledge the financial support of the Dutch Health Council. We also thank Anton van Boxtel of the Health Council for his help in providing us with data from a survey conducted by Dialyse Groep Nederland.

PY - 1993

Y1 - 1993

N2 - Recombinant human erythropoietin is an efficacious therapy in treatment of the anemia of end-stage renal failure. However, the scale of impact on quality of life and medical care resources remains uncertain. By reviewing the literature we evaluate cost-effectiveness of recombinant human erythropoietin and show how previous studies may have implicitly overestimated cost-effectiveness.

AB - Recombinant human erythropoietin is an efficacious therapy in treatment of the anemia of end-stage renal failure. However, the scale of impact on quality of life and medical care resources remains uncertain. By reviewing the literature we evaluate cost-effectiveness of recombinant human erythropoietin and show how previous studies may have implicitly overestimated cost-effectiveness.

UR - http://www.scopus.com/inward/record.url?scp=0027427125&partnerID=8YFLogxK

U2 - 10.1017/S0266462300005419

DO - 10.1017/S0266462300005419

M3 - Article

C2 - 8288425

AN - SCOPUS:0027427125

SN - 0266-4623

VL - 9

SP - 490

EP - 504

JO - International Journal of Technology Assessment in Health Care

JF - International Journal of Technology Assessment in Health Care

IS - 4

ER -

Benefits and costs of recombinant human erythropoietin for end-stage renal failure: A review benefits and costs of erythropoietin

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this